adenine has been researched along with Local Neoplasm Recurrence in 97 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase 1, dose-finding study investigated ibrutinib and carfilzomib ± dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (≥2 lines of therapy including bortezomib and an immunomodulatory agent)." | 9.27 | Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. ( Anderson, LD; Bilotti, E; Chang, L; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Graef, T; Holkova, B; Karanes, C; Larson, S; Lee, Y; Lunning, M; Matous, JV; Niesvizky, R; Pak, Y; Salman, Z; Usmani, SZ; Valent, J, 2018) |
| "Patients with multiple myeloma (MM) inevitably relapse on initial treatment regimens, and novel combination therapies are needed." | 6.94 | Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. ( Anderson, LD; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Girnius, S; Karanes, C; Lee, Y; Liu, E; Lunning, M; Matous, JV; Niesvizky, R; Salman, Z; Shustik, C; Stuart, R; Usmani, SZ; Valent, J, 2020) |
| "Amonafide, 300 mg/m2, was administered intravenously over 1 hour daily for 5 consecutive days." | 6.67 | Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A Southwest Oncology Group study. ( Alberts, DS; Craig, JB; Liu, PY; Malviya, VK; O'Sullivan, J; O'Toole, R; Rosenoff, S; Surwit, E; Ward, JH; Yu, A, 1994) |
| "Neuroblastomas are childhood tumors with frequent fatal relapses after induction treatment, which is related to tumor evolution with additional genomic events." | 5.62 | Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma. ( Dolman, MEM; Drost, J; Ebus, ME; Essing, AHW; Hakkert, A; Helleday, T; Hoyng, LL; Koopmans, B; Koster, J; Molenaar, JJ; Molenaar, P; Oka, R; Schild, L; van Boxtel, R; van den Boogaard, ML; van Gerven, MR; Versteeg, R; Zwijnenburg, DA, 2021) |
| "This phase 1, dose-finding study investigated ibrutinib and carfilzomib ± dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (≥2 lines of therapy including bortezomib and an immunomodulatory agent)." | 5.27 | Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. ( Anderson, LD; Bilotti, E; Chang, L; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Graef, T; Holkova, B; Karanes, C; Larson, S; Lee, Y; Lunning, M; Matous, JV; Niesvizky, R; Pak, Y; Salman, Z; Usmani, SZ; Valent, J, 2018) |
| "In patients with hepatitis B-related HCC, adefovir antiviral therapy reduced late HCC recurrence and significantly improved overall survival after R0 hepatic resection." | 5.20 | Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. ( Huang, G; Lau, WY; Pan, ZY; Shen, F; Wang, ZG; Wu, MC; Yuan, SX; Zhou, WP, 2015) |
| " We sought to identify the optimal dosing combination, based on efficacy and toxicity, utilizing a continual reassessment method of 6 combinations of IBR (280 mg, 420 mg, and 560 mg by mouth daily) and VEN (max dose of 200 mg and 400 mg by mouth daily)." | 3.11 | Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. ( Budde, LE; Chen, RW; Cohen, JB; Kahl, BS; Petroni, GR; Portell, CA; Varhegyi, NE; Wages, NA; Williams, ME, 2022) |
| "Patients with multiple myeloma (MM) inevitably relapse on initial treatment regimens, and novel combination therapies are needed." | 2.94 | Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. ( Anderson, LD; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Girnius, S; Karanes, C; Lee, Y; Liu, E; Lunning, M; Matous, JV; Niesvizky, R; Salman, Z; Shustik, C; Stuart, R; Usmani, SZ; Valent, J, 2020) |
| "Most patients with follicular lymphoma (FL) experience multiple relapses necessitating subsequent lines of therapy." | 2.87 | Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. ( Anderson, DM; Ansell, SM; Bartlett, NL; Costello, BA; Fehniger, TA; Gomez, F; Griffith, M; Griffith, OL; Krysiak, K; Kuruvilla, JG; LaPlant, BR; Qi, J; Ramirez, C; Reeder, CB; Siegel, BA; Thye, LS, 2018) |
| "Amonafide, 300 mg/m2, was administered intravenously over 1 hour daily for 5 consecutive days." | 2.67 | Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A Southwest Oncology Group study. ( Alberts, DS; Craig, JB; Liu, PY; Malviya, VK; O'Sullivan, J; O'Toole, R; Rosenoff, S; Surwit, E; Ward, JH; Yu, A, 1994) |
| "Amonafide has significant toxicity but appears to be an inactive drug in metastatic or recurrent squamous cell cancer of the cervix." | 2.67 | Evaluation of amonafide in cervical cancer, phase II. A SWOG study. ( Alberts, DS; Craig, JB; Hannigan, EV; Liu, PY; Malviya, VK; Surwit, EA, 1992) |
| "Here, we report a case of an elderly chronic lymphocytic leukemia patient who developed multiple inflamed lesions and lower limb cellulitis in 100 days after initiating ibrutinib therapy." | 2.66 | Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review. ( Albattah, A; Alhijji, I; Alokka, R; Elazzazy, S; Ghasoub, R; Nemir, A; Taha, R, 2020) |
| " Outcomes assessed included overall response rate (ORR), complete response (CR) rate, overall survival (OS), progression-free survival (PFS), and adverse events." | 2.61 | Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma. ( Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J, 2019) |
| "Those who develop disease progression on ibrutinib are a particularly high-risk population with poor outcomes." | 2.58 | Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy. ( Ayed, AO; Parikh, SA, 2018) |
| "Waldenström macroglobulinemia is defined by the presence of monoclonal immunoglobulin IgM type (M-IgM) and evidence of lymphoplasmacytic bone marrow infiltration." | 2.53 | [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. ( Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S, 2016) |
| "Neuroblastomas are childhood tumors with frequent fatal relapses after induction treatment, which is related to tumor evolution with additional genomic events." | 1.62 | Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma. ( Dolman, MEM; Drost, J; Ebus, ME; Essing, AHW; Hakkert, A; Helleday, T; Hoyng, LL; Koopmans, B; Koster, J; Molenaar, JJ; Molenaar, P; Oka, R; Schild, L; van Boxtel, R; van den Boogaard, ML; van Gerven, MR; Versteeg, R; Zwijnenburg, DA, 2021) |
| "Most patients with chronic lymphocytic leukemia (CLL) present with multiple comorbidities." | 1.48 | Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. ( Alqahtani, H; Amrock, SM; Choi, M; Churnetski, M; Cohen, JB; Danilov, AV; Gordon, MJ; Hoff, S; James, S; Kittai, A; Manda, S; Persky, D; Rivera, X; Spurgeon, SE, 2018) |
| "Richter syndrome (RS) is a rare event in chronic lymphocytic leukemia (CLL) that is influenced by biological factors and prior CLL treatments." | 1.46 | Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome. ( Albi, E; Ascani, S; Aureli, P; Baldoni, S; Del Papa, B; Di Ianni, M; Dorillo, E; Falzetti, F; Sportoletti, P, 2017) |
| "Microsatellite instability was detected in nine cases in both procedures." | 1.34 | Shorter CAG repeat length in the AR gene is associated with poor outcome in head and neck cancer. ( Canevari, Rde A; dos Santos, RM; Kowalski, LP; Magrin, J; Nishimoto, IN; Poli-Frederico, RC; Rainho, CA; Rogatto, SR; Rosa, FE, 2007) |
| "In contrast, colorectal cancers with codon 12 aspartic acid substitutions accounted for most of the distant hematogenous deposits (P < 0." | 1.29 | Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. ( Christensen, S; Finkelstein, SD; Sayegh, R; Swalsky, PA, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (4.12) | 18.2507 |
| 2000's | 1 (1.03) | 29.6817 |
| 2010's | 60 (61.86) | 24.3611 |
| 2020's | 32 (32.99) | 2.80 |
| Authors | Studies |
|---|---|
| van den Boogaard, ML | 1 |
| Oka, R | 1 |
| Hakkert, A | 1 |
| Schild, L | 1 |
| Ebus, ME | 1 |
| van Gerven, MR | 1 |
| Zwijnenburg, DA | 1 |
| Molenaar, P | 1 |
| Hoyng, LL | 1 |
| Dolman, MEM | 1 |
| Essing, AHW | 1 |
| Koopmans, B | 1 |
| Helleday, T | 1 |
| Drost, J | 1 |
| van Boxtel, R | 1 |
| Versteeg, R | 1 |
| Koster, J | 1 |
| Molenaar, JJ | 1 |
| Akpinar, S | 1 |
| Dogu, MH | 1 |
| Celik, S | 1 |
| Ekinci, O | 1 |
| Hindilerden, IY | 1 |
| Dal, MS | 1 |
| Davulcu, EA | 1 |
| Tekinalp, A | 1 |
| Hindilerden, F | 1 |
| Ozcan, BG | 1 |
| Hacibekiroglu, T | 1 |
| Erkurt, MA | 1 |
| Bagci, M | 1 |
| Namdaroglu, S | 1 |
| Korkmaz, G | 1 |
| Bilgir, O | 1 |
| Cagliyan, GA | 1 |
| Ozturk, HBA | 1 |
| Serin, I | 1 |
| Tiryaki, TO | 1 |
| Ozatli, D | 1 |
| Korkmaz, S | 1 |
| Ulas, T | 1 |
| Eser, B | 1 |
| Turgut, B | 1 |
| Altuntas, F | 1 |
| Portell, CA | 1 |
| Wages, NA | 1 |
| Kahl, BS | 1 |
| Budde, LE | 1 |
| Chen, RW | 1 |
| Cohen, JB | 3 |
| Varhegyi, NE | 1 |
| Petroni, GR | 1 |
| Williams, ME | 1 |
| Wang, M | 3 |
| Ramchandren, R | 2 |
| Chen, R | 2 |
| Karlin, L | 1 |
| Chong, G | 1 |
| Jurczak, W | 2 |
| Wu, KL | 1 |
| Bishton, M | 1 |
| Collins, GP | 2 |
| Eliadis, P | 1 |
| Peyrade, F | 1 |
| Lee, Y | 3 |
| Eckert, K | 1 |
| Neuenburg, JK | 2 |
| Tam, CS | 2 |
| Qualls, D | 1 |
| Lam, HY | 1 |
| Whiting, K | 1 |
| Kumar, A | 1 |
| Matasar, M | 1 |
| Owens, C | 1 |
| Nichols, C | 1 |
| Espeleta, JA | 1 |
| Qiu, A | 1 |
| Subzwari, S | 1 |
| Biggar, E | 1 |
| Seshan, V | 1 |
| Salles, G | 1 |
| Younes, A | 1 |
| Batlevi, C | 1 |
| Eichenauer, DA | 1 |
| Bühnen, I | 1 |
| Plütschow, A | 1 |
| Kobe, C | 1 |
| Dietlein, M | 1 |
| Wendtner, CM | 1 |
| Thorspecken, S | 1 |
| Topp, MS | 1 |
| Mauser, M | 1 |
| von Tresckow, B | 1 |
| Fuchs, M | 1 |
| Borchmann, P | 1 |
| Engert, A | 1 |
| Black, GS | 1 |
| Huang, X | 6 |
| Qiao, Y | 1 |
| Tarapcsak, S | 1 |
| Rogers, KA | 2 |
| Misra, S | 1 |
| Byrd, JC | 7 |
| Marth, GT | 1 |
| Stephens, DM | 1 |
| Woyach, JA | 4 |
| Sancho, JM | 1 |
| Marín-Niebla, A | 1 |
| Fernández, S | 1 |
| Capote, FJ | 1 |
| Cañigral, C | 1 |
| Grande, C | 1 |
| Donato, E | 1 |
| Zeberio, I | 1 |
| Puerta, JM | 1 |
| Rivas, A | 1 |
| Pérez-Ceballos, E | 1 |
| Vale, A | 1 |
| Martín García-Sancho, A | 1 |
| Salar, A | 1 |
| González-Barca, E | 1 |
| Teruel, A | 1 |
| Pastoriza, C | 1 |
| Conde-Royo, D | 1 |
| Sánchez-García, J | 1 |
| Barrenetxea, C | 1 |
| Arranz, R | 1 |
| Hernández-Rivas, JÁ | 2 |
| Ramírez, MJ | 1 |
| Jiménez, A | 2 |
| Rubio-Azpeitia, E | 1 |
| Epperla, N | 1 |
| Zhao, Q | 1 |
| Chowdhury, SM | 1 |
| Shea, L | 1 |
| Moyo, TK | 1 |
| Reddy, N | 1 |
| Sheets, J | 1 |
| Weiner, DM | 1 |
| Geethakumari, PR | 1 |
| Kandarpa, M | 1 |
| Bruno, XJ | 1 |
| Thomas, C | 1 |
| Churnetski, MC | 1 |
| Hsu, A | 1 |
| Zurbriggen, L | 1 |
| Tan, C | 1 |
| Lindsey, K | 1 |
| Maakaron, J | 1 |
| Caimi, PF | 1 |
| Torka, P | 1 |
| Bello, C | 1 |
| Ayyappan, S | 1 |
| Karmali, R | 1 |
| Kim, SH | 2 |
| Kress, A | 1 |
| Kothari, S | 1 |
| Sawalha, Y | 1 |
| Christian, B | 2 |
| David, KA | 1 |
| Greenwell, IB | 1 |
| Janakiram, M | 1 |
| Kenkre, VP | 1 |
| Olszewski, AJ | 1 |
| Palmisiano, N | 1 |
| Umyarova, E | 1 |
| Wilcox, RA | 1 |
| Awan, FT | 2 |
| Alderuccio, JP | 1 |
| Barta, SK | 1 |
| Grover, NS | 1 |
| Ghosh, N | 2 |
| Bartlett, NL | 3 |
| Herrera, AF | 1 |
| Shouse, G | 1 |
| Freeman, CL | 1 |
| Pararajalingam, P | 1 |
| Jin, L | 1 |
| Balasubramanian, S | 1 |
| Jiang, A | 1 |
| Xu, W | 3 |
| Grau, M | 1 |
| Zapukhlyak, M | 1 |
| Boyle, M | 1 |
| Hodkinson, B | 1 |
| Schaffer, M | 1 |
| Enny, C | 1 |
| Deshpande, S | 2 |
| Sun, S | 1 |
| Vermeulen, J | 1 |
| Morin, RD | 1 |
| Scott, DW | 1 |
| Lenz, G | 1 |
| Rai, S | 1 |
| Tanizawa, Y | 1 |
| Cai, Z | 1 |
| Huang, YJ | 1 |
| Taipale, K | 1 |
| Tajimi, M | 1 |
| Vorobyev, VI | 1 |
| Gemdzhian, EG | 1 |
| Fedorova, LV | 1 |
| Mikhailova, NB | 1 |
| Ilyasov, RK | 1 |
| Kaleikina, LP | 1 |
| Trubyakova, OS | 1 |
| Kaplanov, KD | 1 |
| Melnichenko, EV | 1 |
| Martynova, EV | 1 |
| Yakovleva, EP | 1 |
| Li, OY | 1 |
| Tarasenko, EV | 1 |
| Chumakova, EP | 1 |
| Bulieva, NB | 1 |
| Nesterova, ES | 1 |
| Margolin, OV | 1 |
| Zherebtsova, VA | 1 |
| Butaev, LS | 1 |
| Ptushkin, VV | 1 |
| Skrabek, P | 1 |
| Assouline, S | 1 |
| Christofides, A | 1 |
| MacDonald, D | 1 |
| Prica, A | 1 |
| Sangha, R | 1 |
| Matthews, BA | 1 |
| Sehn, LH | 1 |
| Jeon, YW | 1 |
| Yoon, S | 1 |
| Min, GJ | 1 |
| Park, SS | 1 |
| Park, S | 3 |
| Yoon, JH | 1 |
| Lee, SE | 1 |
| Cho, BS | 1 |
| Eom, KS | 1 |
| Kim, YJ | 1 |
| Kim, HJ | 2 |
| Lee, S | 1 |
| Min, CK | 1 |
| Lee, JW | 1 |
| Cho, SG | 1 |
| Telford, C | 1 |
| Kabadi, SM | 1 |
| Abhyankar, S | 1 |
| Song, J | 2 |
| Signorovitch, J | 1 |
| Zhao, J | 1 |
| Yao, Z | 1 |
| Nakamura, K | 1 |
| Saburi, M | 1 |
| Kondo, Y | 1 |
| Soga, Y | 1 |
| Itani, K | 1 |
| Kohno, K | 1 |
| Otsuka, M | 1 |
| Nakayama, T | 1 |
| Chari, A | 2 |
| Cornell, RF | 2 |
| Gasparetto, C | 2 |
| Karanes, C | 2 |
| Matous, JV | 2 |
| Niesvizky, R | 2 |
| Lunning, M | 2 |
| Usmani, SZ | 2 |
| Anderson, LD | 2 |
| Chhabra, S | 2 |
| Girnius, S | 1 |
| Shustik, C | 1 |
| Stuart, R | 1 |
| Salman, Z | 2 |
| Liu, E | 1 |
| Valent, J | 2 |
| Lee, HJ | 1 |
| Schmelz, JL | 1 |
| Cramer, F | 1 |
| Romaguera, JE | 1 |
| Badillo, M | 1 |
| Furman, RR | 3 |
| Coutre, SE | 2 |
| Flinn, IW | 1 |
| Burger, JA | 6 |
| Blum, K | 1 |
| Sharman, JP | 2 |
| Wierda, W | 1 |
| Zhao, W | 3 |
| Heerema, NA | 2 |
| Luan, Y | 1 |
| Liu, EA | 1 |
| Dean, JP | 2 |
| O'Brien, S | 5 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 1 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Yan, Z | 1 |
| Zhou, L | 1 |
| Zhao, Y | 3 |
| Wang, J | 7 |
| Huang, L | 2 |
| Hu, K | 1 |
| Liu, H | 4 |
| Wang, H | 3 |
| Guo, Z | 1 |
| Song, Y | 1 |
| Huang, H | 4 |
| Yang, R | 1 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 1 |
| Wu, S | 2 |
| Cheng, T | 1 |
| Zhou, X | 1 |
| Wang, B | 4 |
| Zhang, Q | 4 |
| Wu, X | 2 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Hashimoto, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Jiao, J | 3 |
| Gai, QY | 3 |
| Wang, W | 3 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Wang, X | 6 |
| Yao, LP | 1 |
| Qin, QP | 1 |
| Wang, ZY | 1 |
| Liu, J | 4 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 1 |
| Zhu, J | 2 |
| Jiang, H | 1 |
| He, C | 2 |
| Xiao, Z | 1 |
| Xu, J | 2 |
| Sun, Q | 1 |
| Han, D | 1 |
| Lei, H | 1 |
| Zhao, K | 2 |
| Zhu, L | 1 |
| Li, X | 5 |
| Fu, H | 2 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Sun, Y | 4 |
| Liu, Z | 3 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Lin, L | 3 |
| Shao, J | 1 |
| Sun, M | 1 |
| Xu, G | 1 |
| Zhang, X | 8 |
| Xu, N | 1 |
| Wang, R | 1 |
| Liu, S | 1 |
| He, H | 1 |
| Dong, X | 2 |
| Yang, M | 2 |
| Yang, Q | 1 |
| Duan, S | 1 |
| Yu, Y | 2 |
| Han, J | 2 |
| Zhang, C | 3 |
| Chen, L | 2 |
| Yang, X | 1 |
| Li, W | 3 |
| Wang, T | 2 |
| Campbell, DA | 1 |
| Gao, K | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 1 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 4 |
| Yao, L | 2 |
| Sun, L | 3 |
| Zhu, Z | 1 |
| Naren, N | 1 |
| Zhang, XX | 2 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Lee, JH | 3 |
| Yoo, JS | 1 |
| Kim, Y | 1 |
| Kim, JS | 2 |
| Lee, EJ | 1 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simon, M | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 1 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 1 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Yang, S | 1 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 1 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Gao, S | 1 |
| Zhai, X | 1 |
| Wang, C | 2 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Lu, Y | 1 |
| Yan, R | 1 |
| Zhang, Y | 6 |
| Hu, Z | 1 |
| You, Q | 1 |
| Cai, Q | 1 |
| Yang, D | 1 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 1 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 1 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Park, JI | 1 |
| Wang, Y | 9 |
| Zhao, R | 1 |
| Gu, Z | 1 |
| Dong, C | 2 |
| Guo, G | 1 |
| Li, L | 5 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Zhu, X | 1 |
| Xu, H | 2 |
| Yang, G | 2 |
| Lin, Z | 1 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 2 |
| An, Z | 1 |
| Jiang, J | 2 |
| Li, J | 7 |
| Du, S | 1 |
| Zhou, H | 1 |
| Cui, J | 1 |
| Wu, W | 1 |
| Liu, Y | 7 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 1 |
| Choi, GH | 1 |
| Choi, J | 1 |
| Lim, YS | 1 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Zhao, L | 1 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 1 |
| Yang, P | 1 |
| Yu, X | 2 |
| Wu, Y | 2 |
| Zhang, H | 2 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Wu, G | 2 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 2 |
| Carreno, J | 1 |
| Kloner, RA | 1 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 1 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 1 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 2 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 1 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Sun, J | 2 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 2 |
| Zheng, S | 2 |
| Ma, L | 1 |
| Wang, L | 4 |
| Hu, T | 1 |
| Wang, F | 1 |
| Han, Z | 1 |
| Yin, Z | 1 |
| Ge, X | 1 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 1 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Yang, Y | 4 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 1 |
| Li, Y | 4 |
| Du, Q | 1 |
| Hao, P | 1 |
| Cao, X | 1 |
| Li, CX | 1 |
| Zhao, S | 1 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Guo, L | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 1 |
| Xie, Y | 2 |
| Tang, J | 3 |
| Chen, Z | 3 |
| Luo, W | 1 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 1 |
| Zhou, Z | 2 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 1 |
| Zhang, Z | 2 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Zhang, J | 3 |
| Guo, W | 1 |
| Liu, M | 2 |
| Liu, T | 2 |
| Chen, D | 5 |
| Luo, K | 1 |
| He, Z | 2 |
| Zheng, G | 1 |
| Xu, F | 1 |
| Sun, W | 1 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Shi, X | 1 |
| Kang, S | 1 |
| Duan, W | 1 |
| Zhang, S | 2 |
| Feng, J | 2 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 1 |
| Shang, Q | 1 |
| Yang, Z | 2 |
| Jiang, X | 2 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 1 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 1 |
| Quan, M | 1 |
| Dong, J | 1 |
| Bai, J | 1 |
| Han, R | 1 |
| Cai, Y | 1 |
| Lv, YQ | 1 |
| Chen, Q | 1 |
| Lyu, HD | 1 |
| Deng, L | 1 |
| Zhou, D | 1 |
| Xiao, X | 1 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Gao, F | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 1 |
| Otano, I | 1 |
| Alvarez, M | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 1 |
| Yu, Q | 1 |
| Zhou, C | 1 |
| Liu, C | 2 |
| Liu, W | 1 |
| Chen, W | 1 |
| Yin, Y | 1 |
| Li, CW | 1 |
| Hsu, JL | 1 |
| Zhou, Q | 1 |
| Hu, B | 1 |
| Fu, P | 1 |
| Atyah, M | 1 |
| Ma, Q | 2 |
| Xu, Y | 1 |
| Dong, Q | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Chen, X | 3 |
| Cao, Q | 1 |
| Yuan, X | 1 |
| Nie, W | 1 |
| Yang, J | 2 |
| Shao, B | 1 |
| Ma, X | 1 |
| Bi, Z | 1 |
| Liang, X | 1 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 1 |
| Wei, Y | 1 |
| Wei, X | 2 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 1 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 1 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 1 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 1 |
| Bi, W | 1 |
| Tang, H | 1 |
| Cui, Y | 1 |
| Zhang, L | 4 |
| Fan, H | 1 |
| Yu, H | 1 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 2 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Lee, C | 1 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 1 |
| Li, C | 3 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Jin, X | 1 |
| Pang, B | 1 |
| Liu, Q | 2 |
| Liu, X | 3 |
| Huang, Y | 3 |
| Josephine Fauci, A | 1 |
| Ma, Y | 1 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 2 |
| Chua, H | 1 |
| Wang, K | 1 |
| Ou, Y | 1 |
| Huang, M | 1 |
| Zhu, Y | 1 |
| Yu, J | 1 |
| Tian, J | 1 |
| Zhao, M | 1 |
| Hu, J | 1 |
| Yao, C | 1 |
| Zhang, B | 1 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 1 |
| Chi, T | 1 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 1 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Han, G | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Park, JH | 2 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 1 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 2 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 1 |
| Rimoldi, S | 1 |
| Noll, G | 1 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 1 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 1 |
| Kang, J | 1 |
| Cho, JH | 1 |
| Oh, S | 1 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 1 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 1 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 1 |
| Levinger, I | 1 |
| Vogrin, S | 1 |
| Neil, CJ | 1 |
| Allen, JD | 1 |
| Lv, Y | 1 |
| Yuan, R | 1 |
| Cai, B | 1 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Yang, C | 2 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 1 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 1 |
| Kim, MJ | 1 |
| Baek, SH | 1 |
| Choi, M | 2 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 2 |
| Lee, JO | 2 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 2 |
| Fang, Z | 1 |
| Wei, F | 1 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Guo, Y | 1 |
| Shen, Y | 1 |
| Wang, Q | 2 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 2 |
| Li, Z | 3 |
| Liang, H | 1 |
| Xu, X | 1 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 1 |
| Wang, P | 1 |
| Mi, K | 1 |
| Cheng, J | 1 |
| Gu, C | 1 |
| Huang, J | 2 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Zheng, Y | 1 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Zhou, Y | 3 |
| Xue, H | 1 |
| Zhang, W | 1 |
| Ruan, Z | 1 |
| Li, S | 4 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 1 |
| Kong, F | 1 |
| Lin, S | 1 |
| Wang, Z | 2 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Yan, X | 1 |
| Ma, C | 1 |
| Tang, Y | 1 |
| Kong, X | 1 |
| Lu, J | 1 |
| Zhang, M | 2 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 1 |
| Le Foll, B | 1 |
| Xia, Y | 2 |
| Chen, S | 1 |
| Luo, M | 1 |
| Wu, J | 1 |
| Cai, S | 1 |
| He, Y | 2 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Yuan, Q | 1 |
| Sherrell, PC | 1 |
| Chen, J | 2 |
| Bi, X | 1 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Xue, J | 1 |
| Wu, P | 1 |
| Xu, L | 1 |
| Yuan, Y | 1 |
| Luo, J | 1 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Hu, Y | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Srivastava, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, JS | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 1 |
| Zhang, G | 1 |
| Jiang, F | 1 |
| Meng, X | 1 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 1 |
| Tan, SJ | 1 |
| Xin, S | 1 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 1 |
| Yan, W | 1 |
| Luo, L | 1 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 1 |
| Hassan, HM | 1 |
| Jiang, Z | 1 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 1 |
| Bentley, RF | 1 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 1 |
| Liang, J | 1 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 1 |
| Chu, Q | 1 |
| Wu, MC | 3 |
| Lu, X | 1 |
| Wang, D | 1 |
| Hu, M | 1 |
| Shen, H | 1 |
| Yao, M | 1 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 1 |
| Xiong, X | 1 |
| Peng, X | 1 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 1 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Wang, HY | 1 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 1 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 1 |
| Sun, X | 1 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 1 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Gao, Y | 1 |
| Cao, WH | 1 |
| Lyu, J | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Dong, Z | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 1 |
| Li, LM | 1 |
| Pan, L | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 1 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 1 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 2 |
| Sun, YH | 1 |
| Zhang, HB | 1 |
| Badar, T | 1 |
| Astle, J | 1 |
| Kakar, IK | 1 |
| Zellner, K | 1 |
| Hari, PN | 1 |
| Hamadani, M | 1 |
| Lauer, EM | 1 |
| Waterhouse, M | 1 |
| Braig, M | 1 |
| Mutter, J | 1 |
| Bleul, S | 1 |
| Duque-Afonso, J | 1 |
| Duyster, J | 1 |
| Marks, R | 2 |
| Reinacher, PC | 1 |
| Prinz, M | 1 |
| Illerhaus, G | 1 |
| Finke, J | 1 |
| Schorb, E | 1 |
| Scherer, F | 1 |
| Molica, S | 1 |
| Baumann, TS | 1 |
| Lentini, M | 1 |
| Levato, L | 1 |
| Delgado, J | 2 |
| Montserrat, E | 1 |
| Puła, B | 2 |
| Długosz-Danecka, M | 2 |
| Salomon-Perzyński, A | 1 |
| Szymczyk, A | 2 |
| Subocz, E | 2 |
| Budziszewska, BK | 2 |
| Rybka, J | 2 |
| Gil, L | 2 |
| Waszczuk-Gajda, A | 2 |
| Iskierka-Jażdżewska, E | 3 |
| Zaucha, JM | 2 |
| Osowiecki, M | 2 |
| Piszczek, W | 2 |
| Steckiewicz, P | 2 |
| Szukalski, Ł | 1 |
| Hus, M | 2 |
| Lech-Marańda, E | 2 |
| Jamroziak, K | 3 |
| Solman, IG | 1 |
| Blum, LK | 1 |
| Hoh, HY | 1 |
| Kipps, TJ | 2 |
| Barrientos, JC | 3 |
| Mulligan, SP | 2 |
| Kay, NE | 1 |
| Hillmen, P | 3 |
| Lal, ID | 1 |
| Mongan, A | 1 |
| Marvyin, K | 1 |
| Tjønnfjord, EB | 1 |
| Breland, UM | 1 |
| Tjønnfjord, GE | 1 |
| Niemann, CU | 2 |
| Levin, MD | 1 |
| Dubois, J | 1 |
| Kersting, S | 1 |
| Enggaard, L | 1 |
| Veldhuis, GJ | 1 |
| Mous, R | 1 |
| Mellink, CHM | 1 |
| Dobber, JA | 1 |
| Poulsen, CB | 1 |
| Frederiksen, H | 1 |
| Janssens, A | 2 |
| Schjødt, I | 1 |
| Dompeling, EC | 1 |
| Ranti, J | 1 |
| Mattsson, M | 2 |
| Bellido, M | 1 |
| Tran, HTT | 1 |
| Nasserinejad, K | 1 |
| Kater, AP | 1 |
| Innocenti, I | 1 |
| Sora, F | 1 |
| Autore, F | 1 |
| Chiusolo, P | 1 |
| Giammarco, S | 1 |
| Metafuni, E | 1 |
| Bacigalupo, A | 1 |
| Sica, S | 1 |
| Laurenti, L | 1 |
| Okahashi, N | 1 |
| Uchihara, M | 1 |
| Hoshino, E | 1 |
| Noy, A | 1 |
| de Vos, S | 1 |
| Coleman, M | 1 |
| Martin, P | 3 |
| Flowers, CR | 1 |
| Thieblemont, C | 1 |
| Morschhauser, F | 3 |
| Ma, S | 1 |
| Peles, S | 1 |
| Smith, SD | 1 |
| Chong, E | 1 |
| Cheung, LW | 1 |
| Kwei, K | 1 |
| Hauns, B | 1 |
| Arango-Hisijara, I | 1 |
| Yi, JH | 1 |
| Yoon, DH | 1 |
| Suh, C | 1 |
| Chang, MH | 1 |
| Yang, DH | 1 |
| Jo, JC | 1 |
| Hyun, SY | 1 |
| Eom, HS | 1 |
| Kwon, JH | 1 |
| Han, SH | 1 |
| Lee, SS | 1 |
| Kwak, JY | 1 |
| Kim, DS | 1 |
| Oh, SY | 1 |
| Ryoo, HM | 1 |
| Kim, WS | 1 |
| Roulin, L | 1 |
| Haioun, C | 1 |
| Lemonnier, F | 1 |
| Fu, X | 1 |
| Renaud, L | 1 |
| Bossard, JB | 1 |
| Carpentier, B | 1 |
| Terriou, L | 1 |
| Cambier, N | 1 |
| Chanteau, G | 1 |
| Escure, G | 1 |
| Tilmont, R | 1 |
| Barbieux, S | 1 |
| Wemeau, M | 1 |
| Hieulle, J | 1 |
| Boyle, EM | 1 |
| Tanigawa, T | 1 |
| Sakurai, M | 1 |
| Kato, J | 1 |
| Mizuno, K | 1 |
| Fujita, S | 1 |
| Koda, Y | 1 |
| Kikuchi, T | 1 |
| Shimizu, T | 1 |
| Okamoto, S | 1 |
| Kataoka, K | 1 |
| Denker, S | 1 |
| Bittner, A | 1 |
| Frick, M | 1 |
| Kase, J | 1 |
| Hoffmann, J | 1 |
| Trenker, C | 1 |
| Keller, U | 1 |
| Bogner, C | 1 |
| Hüttmann, A | 1 |
| Dürig, J | 1 |
| Janz, M | 1 |
| Mathas, S | 1 |
| Krohn, U | 1 |
| Na, IK | 1 |
| Bullinger, L | 1 |
| Schmitt, CA | 1 |
| Hutchinson, L | 1 |
| Brown, JR | 2 |
| Reddy, NM | 1 |
| Jaeger, U | 1 |
| Barr, PM | 1 |
| Cymbalista, F | 1 |
| Thornton, P | 1 |
| Caligaris-Cappio, F | 1 |
| Montillo, M | 1 |
| DeVos, S | 1 |
| Moreno, C | 1 |
| Pagel, JM | 1 |
| Munir, T | 1 |
| Chung, D | 1 |
| Lin, J | 1 |
| Gau, L | 1 |
| Chang, B | 2 |
| Cole, G | 1 |
| Hsu, E | 1 |
| James, DF | 2 |
| Albi, E | 1 |
| Baldoni, S | 1 |
| Aureli, P | 1 |
| Dorillo, E | 1 |
| Del Papa, B | 1 |
| Ascani, S | 1 |
| Di Ianni, M | 1 |
| Falzetti, F | 1 |
| Sportoletti, P | 1 |
| Lakshmanan, A | 1 |
| Wolf, C | 1 |
| Garding, A | 1 |
| Filarsky, K | 1 |
| Bahlo, J | 1 |
| Robrecht, S | 1 |
| Becker, N | 1 |
| Zucknick, M | 1 |
| Rouhi, A | 1 |
| Weigel, A | 1 |
| Claus, R | 1 |
| Weichenhan, D | 1 |
| Eichhorst, B | 1 |
| Fischer, K | 1 |
| Hallek, M | 1 |
| Kuchenbauer, F | 1 |
| Plass, C | 1 |
| Döhner, H | 1 |
| Stilgenbauer, S | 1 |
| Lichter, P | 1 |
| Mertens, D | 1 |
| Costello, BA | 1 |
| LaPlant, BR | 1 |
| Ansell, SM | 1 |
| Kuruvilla, JG | 1 |
| Reeder, CB | 1 |
| Thye, LS | 1 |
| Anderson, DM | 1 |
| Krysiak, K | 1 |
| Ramirez, C | 1 |
| Qi, J | 1 |
| Siegel, BA | 1 |
| Griffith, M | 1 |
| Griffith, OL | 1 |
| Gomez, F | 1 |
| Fehniger, TA | 1 |
| Ayed, AO | 1 |
| Parikh, SA | 1 |
| Cramer, P | 1 |
| Fraser, G | 1 |
| Santucci-Silva, R | 1 |
| Grosicki, S | 1 |
| Dilhuydy, MS | 1 |
| Loscertales, J | 1 |
| Rule, S | 2 |
| Goy, A | 3 |
| Traina, S | 1 |
| Chan, EKH | 1 |
| Diels, J | 2 |
| Sengupta, N | 1 |
| Mahler, M | 1 |
| Salman, M | 1 |
| Howes, A | 1 |
| Chanan-Khan, A | 1 |
| Healy, N | 1 |
| Iraqi, W | 1 |
| Aschan, J | 1 |
| Wildgust, M | 1 |
| Peri, AM | 1 |
| Bisi, L | 1 |
| Cappelletti, A | 1 |
| Colella, E | 1 |
| Verga, L | 1 |
| Borella, C | 1 |
| Foresti, S | 1 |
| Migliorino, GM | 1 |
| Gori, A | 1 |
| Bandera, A | 1 |
| Larson, S | 1 |
| Holkova, B | 1 |
| Chang, L | 1 |
| Pak, Y | 1 |
| Graef, T | 1 |
| Bilotti, E | 1 |
| Garbutt, C | 1 |
| Ma, H | 1 |
| Hornicek, FJ | 1 |
| Kan, Q | 1 |
| Shi, H | 1 |
| Duan, Z | 1 |
| Zawirska, D | 1 |
| Kopacz, A | 1 |
| Czyż, J | 1 |
| Warzocha, K | 2 |
| Gordon, MJ | 1 |
| Churnetski, M | 1 |
| Alqahtani, H | 1 |
| Rivera, X | 1 |
| Kittai, A | 1 |
| Amrock, SM | 1 |
| James, S | 1 |
| Hoff, S | 1 |
| Manda, S | 1 |
| Spurgeon, SE | 1 |
| Persky, D | 1 |
| Danilov, AV | 1 |
| Till, BG | 1 |
| Ruppert, AS | 1 |
| Hoffman, C | 1 |
| Lozanski, G | 2 |
| Maddocks, KJ | 1 |
| Moran, ME | 1 |
| Reid, MA | 1 |
| Lucas, M | 1 |
| Whitlow, WT | 1 |
| Jones, JA | 2 |
| Dreyling, M | 1 |
| Hess, G | 1 |
| Auer, R | 1 |
| Kahl, B | 1 |
| Qi, K | 1 |
| Parisi, L | 1 |
| Winqvist, M | 1 |
| Andersson, PO | 1 |
| Asklid, A | 1 |
| Karlsson, K | 1 |
| Karlsson, C | 1 |
| Lauri, B | 1 |
| Lundin, J | 1 |
| Norin, S | 1 |
| Sandstedt, A | 1 |
| Rosenquist, R | 1 |
| Späth, F | 1 |
| Hansson, L | 1 |
| Österborg, A | 1 |
| Grommes, C | 1 |
| Tang, SS | 1 |
| Wolfe, J | 1 |
| Kaley, TJ | 1 |
| Daras, M | 1 |
| Pentsova, EI | 1 |
| Piotrowski, AF | 1 |
| Stone, J | 1 |
| Lin, A | 1 |
| Nolan, CP | 1 |
| Manne, M | 1 |
| Codega, P | 1 |
| Campos, C | 1 |
| Viale, A | 1 |
| Thomas, AA | 1 |
| Berger, MF | 1 |
| Hatzoglou, V | 1 |
| Reiner, AS | 1 |
| Panageas, KS | 1 |
| DeAngelis, LM | 1 |
| Mellinghoff, IK | 1 |
| Grossi, O | 1 |
| Pineau, S | 1 |
| Sadot-Lebouvier, S | 1 |
| Hay, B | 1 |
| Delaunay, J | 1 |
| Miailhe, AF | 1 |
| Bretonnière, C | 1 |
| Jeddi, F | 1 |
| Lavergne, RA | 1 |
| Le Pape, P | 1 |
| Blum, KA | 2 |
| Maddocks, K | 2 |
| Ruan, J | 2 |
| Ridling, L | 1 |
| Dittus, C | 1 |
| Inghirami, G | 1 |
| DiLiberto, M | 1 |
| Chen-Kiang, S | 2 |
| Leonard, JP | 2 |
| Pouvaret, A | 1 |
| Guery, R | 1 |
| Montillet, M | 1 |
| Molina, TJ | 1 |
| Duréault, A | 1 |
| Bougnoux, ME | 1 |
| Galliot, R | 1 |
| Lanternier, F | 1 |
| Delarue, R | 1 |
| Lortholary, O | 1 |
| He, L | 1 |
| Xia, Z | 1 |
| Shen, J | 1 |
| Peng, W | 1 |
| Wen, T | 1 |
| Styskel, BA | 1 |
| Lopez-Mattei, J | 1 |
| Jimenez, CA | 1 |
| Stewart, J | 1 |
| Hagemeister, FB | 1 |
| Faiz, SA | 1 |
| D'Agaro, T | 1 |
| Zucchetto, A | 1 |
| Vit, F | 1 |
| Bittolo, T | 1 |
| Tissino, E | 1 |
| Rossi, FM | 1 |
| Degan, M | 1 |
| Zaja, F | 1 |
| Bulian, P | 1 |
| Bo, MD | 1 |
| Ferrero, S | 1 |
| Ladetto, M | 1 |
| Zamò, A | 1 |
| Gattei, V | 1 |
| Bomben, R | 1 |
| Geyer, MB | 1 |
| Rivière, I | 1 |
| Sénéchal, B | 1 |
| Purdon, TJ | 1 |
| Hsu, M | 1 |
| Devlin, SM | 1 |
| Palomba, ML | 1 |
| Halton, E | 1 |
| Bernal, Y | 1 |
| van Leeuwen, DG | 1 |
| Sadelain, M | 1 |
| Brentjens, RJ | 1 |
| Gohil, SH | 1 |
| Evans, R | 1 |
| Harasser, M | 1 |
| El-Kholy, M | 1 |
| Paredes-Moscosso, SR | 1 |
| Della Peruta, M | 1 |
| Nathwani, AC | 1 |
| Ghasoub, R | 1 |
| Albattah, A | 1 |
| Elazzazy, S | 1 |
| Alokka, R | 1 |
| Nemir, A | 1 |
| Alhijji, I | 1 |
| Taha, R | 1 |
| Soussain, C | 2 |
| Choquet, S | 2 |
| Blonski, M | 1 |
| Leclercq, D | 1 |
| Houillier, C | 2 |
| Rezai, K | 1 |
| Bijou, F | 1 |
| Houot, R | 1 |
| Boyle, E | 2 |
| Gressin, R | 1 |
| Nicolas-Virelizier, E | 1 |
| Barrie, M | 1 |
| Moluçon-Chabrot, C | 1 |
| Lelez, ML | 1 |
| Clavert, A | 1 |
| Coisy, S | 1 |
| Leruez, S | 1 |
| Touitou, V | 1 |
| Cassoux, N | 1 |
| Daniau, M | 1 |
| Ertault de la Bretonnière, M | 1 |
| El Yamani, A | 1 |
| Ghesquières, H | 1 |
| Hoang-Xuan, K | 2 |
| Munoz, J | 1 |
| Morgan, DS | 1 |
| Dang, NH | 1 |
| Knapp, M | 1 |
| Delioukina, M | 1 |
| Kingsley, E | 1 |
| Ping, J | 1 |
| Beaupre, DM | 1 |
| Huang, G | 2 |
| Lau, WY | 2 |
| Wang, ZG | 1 |
| Pan, ZY | 2 |
| Yuan, SX | 1 |
| Shen, F | 2 |
| Zhou, WP | 2 |
| Chiron, D | 1 |
| Di Liberto, M | 1 |
| Sharman, J | 1 |
| Blecua, P | 1 |
| Mathew, S | 1 |
| Vijay, P | 1 |
| Eng, K | 1 |
| Ali, S | 1 |
| Johnson, A | 1 |
| Ely, S | 1 |
| Elemento, O | 1 |
| Mason, CE | 1 |
| Ghia, P | 1 |
| Keating, MJ | 3 |
| Wierda, WG | 3 |
| Hartmann, E | 1 |
| Hoellenriegel, J | 2 |
| Rosin, NY | 1 |
| de Weerdt, I | 1 |
| Jeyakumar, G | 1 |
| Ferrajoli, A | 2 |
| Cardenas-Turanzas, M | 1 |
| Lerner, S | 1 |
| Jorgensen, JL | 1 |
| Nogueras-González, GM | 1 |
| Zacharian, G | 1 |
| Kantarjian, H | 2 |
| Garg, N | 1 |
| Rosenwald, A | 1 |
| Smith, DD | 1 |
| Goldstein, L | 1 |
| Cheng, M | 1 |
| Kunkel, LA | 1 |
| Fardis, M | 1 |
| Hamdy, A | 2 |
| Izumi, R | 2 |
| Buggy, JJ | 2 |
| Clow, F | 1 |
| Jaglowski, S | 1 |
| Flynn, J | 1 |
| Porcu, P | 1 |
| Wei, L | 1 |
| Jenkins, C | 1 |
| Farooqui, MZ | 1 |
| Valdez, J | 1 |
| Martyr, S | 1 |
| Aue, G | 1 |
| Saba, N | 1 |
| Herman, SE | 1 |
| Tian, X | 1 |
| Marti, G | 1 |
| Soto, S | 1 |
| Hughes, TE | 1 |
| Jones, J | 1 |
| Lipsky, A | 1 |
| Pittaluga, S | 1 |
| Stetler-Stevenson, M | 1 |
| Yuan, C | 1 |
| Lee, YS | 1 |
| Pedersen, LB | 1 |
| Geisler, CH | 1 |
| Calvo, KR | 1 |
| Arthur, DC | 1 |
| Maric, I | 1 |
| Childs, R | 1 |
| Young, NS | 1 |
| Wiestner, A | 1 |
| Murray, MY | 1 |
| Zaitseva, L | 1 |
| Auger, MJ | 1 |
| Craig, JI | 1 |
| MacEwan, DJ | 1 |
| Rushworth, SA | 1 |
| Bowles, KM | 1 |
| Fegan, C | 1 |
| Pepper, C | 1 |
| Kim, ES | 1 |
| Dhillon, S | 1 |
| Thompson, PA | 1 |
| O'Brien, SM | 1 |
| Stingo, F | 1 |
| Smith, SC | 1 |
| Estrov, Z | 1 |
| Jain, N | 1 |
| Kantarjian, HM | 1 |
| Yang, H | 1 |
| Zhan, J | 1 |
| Sun, P | 1 |
| Bi, XW | 1 |
| Liu, PP | 1 |
| Li, ZM | 1 |
| Zou, BY | 1 |
| Jiang, WQ | 1 |
| Adam, Z | 1 |
| Pour, L | 1 |
| Krejčí, M | 1 |
| Ševčíková, S | 1 |
| Pourová, E | 1 |
| Ševčíková, E | 1 |
| Král, Z | 1 |
| Mayer, J | 1 |
| Landau, DA | 1 |
| Taylor-Weiner, A | 1 |
| Bozic, I | 1 |
| Sarosiek, K | 1 |
| Stewart, C | 1 |
| Fan, J | 1 |
| Sivina, M | 1 |
| Dubuc, AM | 1 |
| Fraser, C | 1 |
| Han, Y | 1 |
| Livak, KJ | 1 |
| Zou, L | 1 |
| Wan, Y | 1 |
| Konoplev, S | 1 |
| Sougnez, C | 1 |
| Abruzzo, LV | 1 |
| Carter, SL | 1 |
| Davids, MS | 1 |
| Cibulskis, K | 1 |
| Zenz, T | 1 |
| Werner, L | 1 |
| Dal Cin, P | 1 |
| Kharchencko, P | 1 |
| Neuberg, D | 1 |
| Lander, E | 1 |
| Gabriel, S | 1 |
| Letai, A | 1 |
| Weitz, DA | 1 |
| Nowak, MA | 1 |
| Getz, G | 1 |
| Wu, CJ | 1 |
| Sharma, S | 1 |
| Galanina, N | 1 |
| Guo, A | 1 |
| Lee, J | 1 |
| Kadri, S | 1 |
| Van Slambrouck, C | 1 |
| Long, B | 1 |
| Ming, M | 1 |
| Furtado, LV | 1 |
| Segal, JP | 1 |
| Stock, W | 1 |
| Venkataraman, G | 1 |
| Tang, WJ | 1 |
| Lu, P | 1 |
| Chamoun, K | 1 |
| Larrieu-Ciron, D | 1 |
| Al Jijakli, A | 1 |
| Delrieu, V | 1 |
| Delwail, V | 1 |
| Chan, TS | 1 |
| Au-Yeung, R | 1 |
| Chim, CS | 1 |
| Wong, SC | 1 |
| Kwong, YL | 1 |
| Giannopoulos, K | 1 |
| Mądro, E | 1 |
| Hołojda, J | 1 |
| Piotrowska, M | 1 |
| Szeremet, A | 1 |
| Wojciechowska, M | 1 |
| Knopińska-Posłuszny, W | 1 |
| Drozd-Sokołowska, J | 1 |
| Kumiega, B | 1 |
| Kyrcz-Krzemień, S | 1 |
| Hałka, J | 1 |
| Dudziński, M | 1 |
| Wieszczy, P | 1 |
| Robak, T | 1 |
| Hosaka, T | 1 |
| Suzuki, F | 1 |
| Kobayashi, M | 2 |
| Hirakawa, M | 1 |
| Kawamura, Y | 1 |
| Yatsuji, H | 1 |
| Sezaki, H | 1 |
| Akuta, N | 1 |
| Suzuki, Y | 1 |
| Saitoh, S | 1 |
| Arase, Y | 1 |
| Ikeda, K | 1 |
| Kumada, H | 1 |
| Yang, CM | 1 |
| Hou, YY | 1 |
| Chiu, YT | 1 |
| Chen, HC | 1 |
| Chu, ST | 1 |
| Chi, CC | 1 |
| Hsiao, M | 1 |
| Lee, CY | 1 |
| Hsieh, CJ | 1 |
| Lin, YC | 1 |
| Hsieh, YD | 1 |
| Ger, LP | 1 |
| Advani, RH | 1 |
| Smith, SM | 1 |
| Boyd, TE | 1 |
| Grant, B | 1 |
| Kolibaba, KS | 1 |
| Rodriguez, S | 1 |
| Chang, BY | 1 |
| Sukbuntherng, J | 1 |
| Hedrick, E | 1 |
| Fowler, NH | 1 |
| Fu, SY | 1 |
| Rosa, FE | 1 |
| dos Santos, RM | 1 |
| Poli-Frederico, RC | 1 |
| Canevari, Rde A | 1 |
| Nishimoto, IN | 1 |
| Magrin, J | 1 |
| Rainho, CA | 1 |
| Kowalski, LP | 1 |
| Rogatto, SR | 1 |
| Malviya, VK | 2 |
| Liu, PY | 3 |
| O'Toole, R | 1 |
| Alberts, DS | 2 |
| Surwit, E | 1 |
| Rosenoff, S | 1 |
| Ward, JH | 1 |
| Yu, A | 1 |
| O'Sullivan, J | 2 |
| Craig, JB | 2 |
| Finkelstein, SD | 1 |
| Sayegh, R | 1 |
| Christensen, S | 1 |
| Swalsky, PA | 1 |
| Gallion, HH | 1 |
| Alberts, DE | 1 |
| O'Toole, RV | 1 |
| Mills, G | 1 |
| Smith, HO | 1 |
| Hynes, HE | 1 |
| Surwit, EA | 1 |
| Hannigan, EV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-institution Phase I/Ib Study of Ibrutinib With ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma[NCT02419560] | Phase 1 | 37 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma[NCT03112174] | Phase 3 | 352 participants (Actual) | Interventional | 2017-06-29 | Active, not recruiting | ||
| A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia[NCT01109069] | Phase 2 | 199 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Phase 1b/2 Fixed-dose Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Chronic Lymphocytic Leukemia[NCT01105247] | Phase 1/Phase 2 | 133 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma[NCT01980628] | Phase 2 | 63 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Phase 2 Trial of Single-Agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma[NCT01849263] | Phase 2 | 41 participants (Actual) | Interventional | 2013-04-02 | Active, not recruiting | ||
| Obinutuzumab, Ibrutinib, and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (CLL)[NCT02427451] | Phase 1/Phase 2 | 87 participants (Actual) | Interventional | 2015-08-03 | Active, not recruiting | ||
| A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCN[NCT02315326] | Phase 1/Phase 2 | 109 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma[NCT03478514] | Phase 2 | 39 participants (Actual) | Interventional | 2018-09-11 | Active, not recruiting | ||
| A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell Lymphoma[NCT02159755] | Phase 1 | 28 participants (Actual) | Interventional | 2014-05-20 | Active, not recruiting | ||
| A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19[NCT00466531] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2007-03-21 | Active, not recruiting | ||
| Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma[NCT02542514] | Phase 2 | 52 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| A Multicenter Clinical Study of Orelabrutinib Combined With Lenalidomide and Rituximab (OR2) in the Treatment of Recurrent and Refractory CD20+ B-cell Lymphoma[NCT05014100] | Phase 2 | 55 participants (Anticipated) | Interventional | 2021-09-01 | Not yet recruiting | ||
| A Multicenter Open-Label Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma[NCT02077166] | Phase 1/Phase 2 | 138 participants (Actual) | Interventional | 2014-03-13 | Completed | ||
| Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2019-04-11 | Terminated (stopped due to Insufficient accrual) | ||
| A Phase 2 Study of the Combination of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients[NCT01520519] | Phase 2 | 40 participants (Actual) | Interventional | 2012-02-27 | Completed | ||
| Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798] | Phase 3 | 22 participants (Actual) | Interventional | 2019-12-09 | Active, not recruiting | ||
| A Phase I, Dose-escalation Trial of Rituxan and Bendamustine in Combination With Bruton's Tyrosine Kinase Inhibitor, PCI-32765, in Patients With Relapsed Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Indolent Non-Hodgkin's Lymphoma[NCT01479842] | Phase 1 | 48 participants (Actual) | Interventional | 2011-12-07 | Active, not recruiting | ||
| Sequential Triple Therapy With Ibrutinib, Obinutuzumab and Venetoclax in First and Second Line for Patients With Chronic Lymphocytic Leukemia[NCT03755947] | Phase 2 | 3 participants (Actual) | Interventional | 2018-12-01 | Completed | ||
| A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion[NCT01500733] | Phase 2 | 86 participants (Actual) | Interventional | 2012-01-05 | Active, not recruiting | ||
| A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma[NCT03702725] | Phase 1 | 14 participants (Actual) | Interventional | 2019-08-29 | Active, not recruiting | ||
| Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma[NCT00849654] | Phase 1 | 66 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
All death events are due to AE, progressive disease, and other reasons. (NCT01109069)
Timeframe: 30 days after last dose of study drug
| Intervention | Participants (Count of Participants) |
|---|---|
| IBRUTINIB/PCI-32765 | 42 |
Subjects were to receive ibrutinib once daily at the dose level the subject was receiving in the parent study until disease progression or unacceptable toxicity. The study included Screening, Treatment (from the first dose until study drug discontinuation), and Follow-up Phases. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| A LONG-TERM SAFETY STUDY OF BRUTON'S TYROSINE KINASE (BTK) INH | 199 |
A progressive disease confirmed by a CT scan. (NCT01109069)
Timeframe: 30 days after last dose of study drug, continue up to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| IBRUTINIB/PCI-32765 | 70 |
Geometric mean ratio (Fed/Fasted) for PCI-32765 AUClast. The data were collected at 0, 0.5, 1, 2, 4, 6, 24 h post-dose. The AUClast was calculated from 0 up to 24 hours post-dose. (NCT01105247)
Timeframe: Fed was assessed on either Day 8 or Day 15 and Fasted was assessed on the remaining day as cross-over design.
| Intervention | (Number) |
|---|---|
| Food Effect Cohort | 1.65 |
Number of participants who had experienced at least one treatment emergent AEs. (NCT01105247)
Timeframe: From first dose to within 30 days of last dose of PCI-32765
| Intervention | Participants (Number) |
|---|---|
| PCI-32765 | 116 |
| Food Effect | 11 |
Response criteria are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. response requires 50% reduction in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).
| Intervention | Percentage of Participants (Number) |
|---|---|
| Treatment Naive | 71 |
| Relapsed/ Refractory | 75.3 |
| Food Effect | 56.3 |
Criteria for progression are as outlined in the IWCLL 2008 criteria (Hallek 2008) and as assessed by investigator, e.g. progression defined as a 50% increase in lymph node size. (NCT01105247)
Timeframe: The median follow-up time for all treated patients are 21 month, range (0.7 month, 29 months).
| Intervention | Percentage of Participants (Number) |
|---|---|
| Treatment Naive | 96.3 |
| Relapsed/ Refractory | 73.6 |
| Food- Effect | NA |
The DOR analyses is performed on the subset of subjects that achieve CR or PR as determined by IRC. DOR is calculated as the duration of time from the date of first response to the date of progression or death due to any cause. (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.
| Intervention | Months (Median) |
|---|---|
| Ibrutinib | NA |
"ORR is defined as the proportion of subjects who achieved complete response (CR), partial response (PR). Response criteria are as outlined in the International Working Group Criteria for NHL, Cheson (2007), with disease assessments performed by an independent review committee (IRC).~Per Cheson:~CR is defined as disappearance of all evidence of disease. PR is defined as regression of measurable disease and no new sites." (NCT01980628)
Timeframe: Analysis was conducted with the cutoff date of 02 Nov 2017, with a median follow-up time of 33.1 months.
| Intervention | Percentage of Participants (Mean) |
|---|---|
| Single Arm, Intent to Treat Population | 46 |
"Duration of response is defined as the time from first evidence of a response to the first documented time of progressive disease (PD). Response and Progression were assessed using the Cheson et al. Revised Response Criteria for Malignant Lymphoma. > > A CR is defined as the disappearance of all evidence of disease. A PR is defined as ≥ 50% decrease in the sum of the products of dimensions (SPD) of up to 6 largest dominant masses; no increase in size of other nodes and regression on CT, and no increase in size of liver/spleen.Estimated using the method of Kaplan-Meier.>~> Progressive Disease (PD) is defined as any new lesion or increase by ≥ 50% of previously involved sites from nadir." (NCT01849263)
Timeframe: Time from the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | 13.9 |
"Overall response rate defined as a partial response (PR) or complete response (CR) as the objective status at any time during treatment, evaluated using the Cheson et al. Revised Response Criteria for Malignant Lymphoma. Ninety-five percent binomial confidence intervals for the true success proportion will be calculated.~A CR is defined as the disappearance of all evidence of disease. A PR is defined as ≥ 50% decrease in the sum of the products of dimensions (SPD) of up to 6 largest dominant masses; no increase in size of other nodes and regression on CT, and no increase in size of liver/spleen." (NCT01849263)
Timeframe: Up to 5 years
| Intervention | proportion of participants (Number) |
|---|---|
| Treatment (Ibrutinib) | 0.375 |
Overall Survival is defined as the time from registration to death due to any cause. Estimated using the method of Kaplan-Meier. (NCT01849263)
Timeframe: Assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | NA |
Progression-Free Survival is defined as the time from registration to documented progression or death due to any cause, whichever occurs first. Estimated using the method of Kaplan-Meier. (NCT01849263)
Timeframe: Time from registration to progression or death due to any cause, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | 14.0 |
Time to response is defined for all evaluable patients who have achieved a confirmed response as the time from the date of registration to the date at which the patient's objective status is first noted to be a CR or PR.The median and 95% confidence interval will be calculated using the methods of Kaplan-Meier. (NCT01849263)
Timeframe: Time from the date of registration to the date at which the patient's objective status is first noted to be a CR or PR, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | 4.6 |
Time to subsequent treatment is defined as the time from registration to the date of initiation of subsequent treatment for lymphoma. The distribution of time to subsequent treatment will be estimated using the method of Kaplan-Meier. (NCT01849263)
Timeframe: Time from registration to the date of initiation of subsequent treatment for lymphoma, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | 17.7 |
Time to treatment failure is defined as the time from registration to the date of treatment discontinuation due to any reason. The distribution of time to treatment failure will be estimated using the method of Kaplan-Meier. (NCT01849263)
Timeframe: Time from registration to the date of treatment discontinuation due to any reason, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Treatment (Ibrutinib) | 10.0 |
The CR rate was defined as the percentage of participants who achieve a CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma (Cheson 2007), as assessed by the Investigator in response-evaluable population, where CR=disappearance of all evidence of disease, as assessed by the Investigator. (NCT02077166)
Timeframe: Estimated median time on Phase 1b study was 59.6 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) | 33.3 |
| Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) | 0 |
| Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) | 42.9 |
| Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) | 11.1 |
| Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) | 50.0 |
| Phase 1b Total: Enrolled at Lenalidomide Dose 10 to 25 mg (All Dose Levels) | 27.5 |
The ORR was defined as the percentage of participants who achieve either a PR or CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma (Cheson 2007), as assessed by the Investigator in response-evaluable population, where CR=disappearance of all evidence of disease and PR=regression of measurable disease and no new sites. The 95% CI was calculated using the exact method. (NCT02077166)
Timeframe: Estimated median time on study in Phase 1b was 59.6 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) | 44.4 |
| Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) | 0 |
| Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) | 71.4 |
| Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) | 22.2 |
| Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) | 75.0 |
| Phase 1b Total: Enrolled at Lenalidomide Dose 10 to 25 mg (All Dose Levels) | 42.5 |
The dose levels of lenalidomide were explored, and dose escalation of lenalidomide followed the 3+3+3 dose escalation schema. A Dose Level Review Committee evaluated safety data following completion of each dose observation period of the Phase 1b portion. (NCT02077166)
Timeframe: Estimated median time on study in Phase 1b was 59.6 months.
| Intervention | mg (Number) |
|---|---|
| All Phase 1b Participants | 20 |
The CR rate was defined as the percentage of participants who achieve a CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (see Cheson, 2014 for detailed criteria) in response-evaluable population, as assessed by the Investigator. (NCT02077166)
Timeframe: Estimated median time on study in Phase 2 was 35.0 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 2: Enrolled at Lenalidomide Dose 20 mg | 32.1 |
| Phase 2: Enrolled at Lenalidomide Dose 25 mg | 21.9 |
| Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg | 28.2 |
DOR is defined as the time from the date of the first documented response (CR or PR) to the first documented evidence of disease progression (PD) according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014) or death from any cause. For participants who had achieved an overall response but did not die or progress at the time of analysis, DOR was censored on the date of the last adequate post-baseline disease assessment, or on the date of the first occurrence of response (CR or PR) if there was no disease assessment afterwards. 2-sided 95% CI is estimated by Kaplan-Meier method. (NCT02077166)
Timeframe: Estimated median time on study in Phase 2 was 35.0 months.
| Intervention | months (Median) |
|---|---|
| Phase 2: Enrolled at Lenalidomide Dose 20 mg | 38.3 |
| Phase 2: Enrolled at Lenalidomide Dose 25 mg | 28.6 |
| Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg | 38.3 |
The ORR was defined as the percentage of participants who achieve either a partial response (PR) or complete response (CR), according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014), as assessed by the investigator in response-evaluable population. The 95% confidence interval (CI) was calculated using the exact method. (NCT02077166)
Timeframe: Estimated median time on study in Phase 2 was 35.0 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 2: Enrolled at Lenalidomide Dose 20 mg | 52.8 |
| Phase 2: Enrolled at Lenalidomide Dose 25 mg | 43.8 |
| Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg | 49.4 |
OS is defined as the time from the date of the first dose of study drug to the date of death due to any cause. For participants not known to have died at or prior to the database lock date, OS data was censored at the date last known alive. Participants who withdrew consent prior to study closure were censored on the date of the consent withdrawal. 2-sided 95% CI was estimated by Kaplan-Meier method. (NCT02077166)
Timeframe: Estimated median time on study in Phase 2 was 35.0 months.
| Intervention | months (Median) |
|---|---|
| Phase 2: Enrolled at Lenalidomide Dose 20 mg | 14.7 |
| Phase 2: Enrolled at Lenalidomide Dose 25 mg | 11.6 |
| Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg | 14.2 |
PFS is defined as the time from the date of the first dose of study drug to confirmed PD according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014) or death from any cause, whichever occurred first. For participants without disease progression or death, PFS data was censored at the date of the last tumor assessment. 2 sided 95% CI is estimated by Kaplan-Meier method. (NCT02077166)
Timeframe: Estimated median time on study in Phase 2 was 35.0 months.
| Intervention | months (Median) |
|---|---|
| Phase 2: Enrolled at Lenalidomide Dose 20 mg | 5.4 |
| Phase 2: Enrolled at Lenalidomide Dose 25 mg | 4.7 |
| Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg | 5.4 |
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization > 24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. AEs that started or worsened during the treatment-emergent period and all possibly related or related AEs were considered TEAEs. Related events were those that were considered possibly related or related to study drug per investigator's judgment. Events were graded per the national Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03: Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=life-threatening; grade 5=death. (NCT02077166)
Timeframe: From first dose of study drug up to 30 days after last dose of study drug. Phase 1b median duration of ibrutinib exposure was 4.4 months; median duration of lenalidomide exposure was 4.4 months; median total number of doses of rituximab received was 4.0.
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | Any Grade >=3 TEAE | Any Study Drug-Related TEAE | Any Grade >=3 Study Drug-Related TEAE | Any Ibrutinib-Related TEAE | Any Grade >=3 Ibrutinib-Related TEAE | Any Lenalidomide-Related TEAE | Any Grade >=3 Lenalidomide-Related TEAE | Any Rituximab-Related TEAE | Any Grade >= 3 Rituximab-Related TEAE | Any TEAE Leading to Dose Reduction of Any Study Drug | Any TEAE Leading to Dose Reduction of Ibrutinib | Any TEAE Leading to Dose Reduction of Lenalidomide | Any TEAE Leading to Dose Delay of Any Study Drug | Any TEAE Leading to Dose Delay of Ibrutinib | Any TEAE Leading to Dose Delay of Lenalidomide | Any TEAE Leading to Dose Delay of Rituximab | Any TEAE Leading to Discontinuation of Any Study Drug | Any TEAE Leading to Discontinuation of Ibrutinib Dose | Any TEAE Leading to Discontinuation of Lenalidomide Dose | Any TEAE Leading to Discontinuation of Rituximab Dose | Any Serious TEAE | Any Grade >=3 Serious TEAE | Any Treatment-Related Serious TEAE | Any Ibrutinib-Related Serious TEAE | Any Lenalidomide-Related Serious TEAE | Any Rituximab-Related Serious TEAE | Any Fatal TEAE | |
| Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) | 7 | 6 | 5 | 3 | 5 | 3 | 5 | 3 | 4 | 2 | 0 | 0 | 0 | 4 | 4 | 3 | 1 | 2 | 2 | 2 | 2 | 6 | 6 | 2 | 2 | 2 | 2 | 2 |
| Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) | 12 | 11 | 12 | 10 | 12 | 10 | 12 | 9 | 6 | 1 | 4 | 3 | 2 | 6 | 6 | 6 | 4 | 4 | 4 | 4 | 3 | 4 | 4 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) | 9 | 9 | 9 | 8 | 9 | 7 | 9 | 8 | 7 | 7 | 4 | 4 | 3 | 7 | 7 | 7 | 6 | 3 | 3 | 3 | 3 | 7 | 6 | 4 | 4 | 4 | 2 | 2 |
| Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) | 9 | 9 | 8 | 7 | 8 | 7 | 8 | 7 | 6 | 5 | 4 | 3 | 4 | 8 | 8 | 7 | 4 | 2 | 2 | 2 | 2 | 5 | 4 | 2 | 2 | 2 | 1 | 1 |
| Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) | 8 | 7 | 8 | 7 | 8 | 6 | 8 | 6 | 7 | 3 | 5 | 3 | 4 | 8 | 8 | 8 | 4 | 1 | 1 | 1 | 1 | 6 | 6 | 3 | 3 | 3 | 0 | 1 |
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization > 24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. AEs that started or worsened during the treatment-emergent period and all possibly related or related AEs were considered TEAEs. Related events were those that were considered possibly related or related to study drug per investigator's judgment. Events were graded per the national Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03: Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=life-threatening; grade 5=death. (NCT02077166)
Timeframe: From first dose of study drug up to 30 days after last dose of study drug. Phase 2 median duration of ibrutinib exposure was 4.9 months; median duration of lenalidomide exposure was 4.7 months; median total number of doses of rituximab received was 5.0.
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | Any Grade >=3 TEAE | Any Study Drug-Related TEAE | Any Grade >=3 Study Drug-Related TEAE | Any Ibrutinib-Related TEAE | Any Grade >=3 Ibrutinib-Related TEAE | Any Lenalidomide-Related TEAE | Any Grade >=3 Lenalidomide-Related TEAE | Any Rituximab-Related TEAE | Any Grade >= 3 Rituximab-Related TEAE | Any TEAE Leading to Dose Reduction of Any Study Drug | Any TEAE Leading to Dose Reduction of Ibrutinib | Any TEAE Leading to Dose Reduction of Lenalidomide | Any TEAE Leading to Dose Delay of Any Study Drug | Any TEAE Leading to Dose Delay of Ibrutinib | Any TEAE Leading to Dose Delay of Lenalidomide | Any TEAE Leading to Dose Delay of Rituximab | Any TEAE Leading to Discontinuation of Any Study Drug | Any TEAE Leading to Discontinuation of Ibrutinib Dose | Any TEAE Leading to Discontinuation of Lenalidomide Dose | Any TEAE Leading to Discontinuation of Rituximab Dose | Any Serious TEAE | Any Grade >=3 Serious TEAE | Any Treatment-Related Serious TEAE | Any Ibrutinib-Related Serious TEAE | Any Lenalidomide-Related Serious TEAE | Any Rituximab-Related Serious TEAE | Any Fatal TEAE | |
| Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg | 89 | 81 | 85 | 66 | 82 | 60 | 83 | 65 | 62 | 31 | 37 | 21 | 35 | 69 | 66 | 63 | 16 | 18 | 16 | 18 | 10 | 57 | 50 | 28 | 26 | 26 | 9 | 12 |
| Phase 2: Enrolled at Lenalidomide Dose 20 mg | 55 | 51 | 52 | 41 | 50 | 36 | 51 | 40 | 37 | 18 | 23 | 12 | 21 | 40 | 38 | 37 | 10 | 11 | 11 | 11 | 6 | 32 | 29 | 16 | 14 | 16 | 4 | 8 |
| Phase 2: Enrolled at Lenalidomide Dose 25 mg | 34 | 30 | 33 | 25 | 32 | 24 | 32 | 25 | 25 | 13 | 14 | 9 | 14 | 29 | 28 | 26 | 6 | 7 | 5 | 7 | 4 | 25 | 21 | 12 | 12 | 10 | 5 | 4 |
Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Ibrutinib Plus Rituximab | 0 |
Over all Response = complete remission (CR) + partial remission (PR). Complete remission (CR), requiring absence of peripheral blood clonal lymphocytes by immunophenotyping, absence of lymphadenopathy, absence of hepatomegaly or splenomegaly, absence of constitutional symptoms and satisfactory blood counts; positive or negative minimal residual disease (MRD); Partial remission (PR), defined as ≥ 50% fall in lymphocyte count, ≥ 50% reduction in lymphadenopathy or ≥ 50% reduction in liver or spleen, together with improvement in peripheral blood counts (NCT01520519)
Timeframe: 7 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rituximab + PCI-32765 | 37 |
Progression free survival defined as the time interval from treatment to progressive disease or death, whichever happens earlier. Participants in complete remission (CR), partial remission (PR) or stable disease (SD) are all counted as progression-free. Survival or times to progression functions estimated using the Kaplan-Meier method. (NCT01520519)
Timeframe: up to 50 months
| Intervention | Months (Median) |
|---|---|
| Rituximab + PCI-32765 | 45 |
"The primary endpoint was response after 6 cycles of therapy. Overall response rate was calculated as complete response plus partial response, based on the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2008 criteria.as follows:~Complete response (CR): all group A and group B criteria are met~Group A criteria: resolution of enlarged lymph nodes, normal size spleen and liver, absolute lymphocyte count < 4,000/uL, normocellular bone marrow with < 30% lymphocytes without nodules~Group B criteria: improved blood count (platelet count > 100,000/uL, hemoglobin > 11.0 g/dL, neutrophils > 1,500/uL)~Partial response (PR): at least 2 of the group A criteria plus one of the group B criteria are met~Group A criteria: >=50% decrease in target lymph nodes, >=50% decrease in spleen size, >=50% decrease in liver size, 50% reduction in marrow infiltrates~Group B criteria: platelet count > 100,000/uL, hemoglobin > 11.0 g/dL, neutrophils > 1,500/uL" (NCT01500733)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Elderly Cohort | 93.9 |
| TP53 Cohort | 95.8 |
11 reviews available for adenine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma.
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Agents; Brentuximab Vedotin; Canada; Clinical Trials | 2019 |
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Benzamides; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Biomarkers, Tumor; Clinical Trials as Topic; Disease P | 2018 |
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy P | 2018 |
Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cellulitis; Ecthyma; Humans; Leukemia, Lymphocyt | 2020 |
Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as To | 2015 |
Patterns of resistance to B cell-receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management.
Topics: Adenine; Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemi | 2015 |
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoc | 2016 |
Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, | 2016 |
How I manage ibrutinib-refractory chronic lymphocytic leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocyt | 2017 |
33 trials available for adenine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
Topics: Adenine; Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyc | 2022 |
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicycl | 2021 |
A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
Topics: Adenine; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrimidines; Quinaz | 2022 |
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group.
Topics: Adenine; Hodgkin Disease; Humans; Lymphocytes; Neoplasm Recurrence, Local; Piperidines | 2022 |
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
Topics: 3' Untranslated Regions; Adenine; Adult; Biological Factors; Humans; Lymphoma, Mantle-Cell; Neoplasm | 2022 |
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso | 2020 |
A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, | 2020 |
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival; | 2020 |
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival; | 2020 |
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival; | 2020 |
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival; | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2020 |
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2021 |
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.
Topics: Adenine; Biomarkers; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasm Recurrence | 2020 |
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2018 |
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; CARD Signaling Adaptor Protei | 2018 |
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the H
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Double-Bl | 2018 |
Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human | 2018 |
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso | 2018 |
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combi | 2018 |
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Antineoplastic Com | 2019 |
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fol | 2019 |
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fol | 2019 |
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fol | 2019 |
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fol | 2019 |
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Topics: Adenine; Adult; Aged; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2019 |
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) net
Topics: Adenine; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; Femal | 2019 |
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2019 |
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2019 |
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2019 |
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2019 |
Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis | 2015 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, M | 2014 |
Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib.
Topics: Adenine; Aged; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug | 2015 |
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Comb | 2015 |
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human | 2015 |
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human | 2015 |
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human | 2015 |
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human | 2015 |
Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110δ, for treating relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adenine; Adult; Aged; Aminoquinolines; Antineoplastic Agents; Disease-Free Survival; Dose-Response R | 2015 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Topics: Adenine; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; | 2013 |
Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A Southwest Oncology Group study.
Topics: Adenine; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; | 1994 |
Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study.
Topics: Adenine; Adult; Aged; Cisplatin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imid | 1992 |
Evaluation of amonafide in cervical cancer, phase II. A SWOG study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Evaluation; Female; Huma | 1992 |
54 other studies available for adenine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastoma.
Topics: Adenine; Child; Cytosine; DNA Damage; DNA Glycosylases; DNA Repair; Female; Guanine; Guanosine; Huma | 2021 |
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Piperidines; Py | 2022 |
Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.
Topics: Adenine; Benzamides; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Recurrence, | 2022 |
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Middle Aged; Neoplasm Recurrence, Local; Piperidines; | 2022 |
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.
Topics: Adenine; Cohort Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasm Recurrence, Local; Piperi | 2022 |
Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; | 2022 |
[Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].
Topics: Adenine; Aged; Clinical Trials as Topic; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; | 2021 |
Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Age | 2019 |
[Ibrutinib therapy for a blastoid variant mantle cell lymphoma patient with early extranodal relapse after autologous stem cell transplantation].
Topics: Adenine; Aged; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Neoplas | 2019 |
Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Hematopoietic Stem Cell Transplantation; | 2020 |
Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
Topics: Adenine; Aged; Aged, 80 and over; Central Nervous System Neoplasms; Female; Humans; Lymphoma; Male; | 2020 |
The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers, Tu | 2020 |
Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resist | 2020 |
Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment.
Topics: Adenine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation | 2020 |
Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
Topics: Adenine; Aged; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, | 2021 |
[Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
Topics: Adenine; Aged; Central Nervous System; Central Nervous System Neoplasms; Humans; Lymphoma, Mantle-Ce | 2020 |
Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis.
Topics: Adenine; Adult; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Republic of | 2021 |
Fatal splenic rupture after discontinuing treatment by ibrutinib and venetoclax in relapse/refractory mantle cell lymphoma.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocycl | 2021 |
Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Het | 2021 |
Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Ner | 2021 |
Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
Topics: Adenine; Adult; Central Nervous System Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; L | 2022 |
Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
Topics: Adenine; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorub | 2022 |
Targeted therapies: Ibrutinib: new option for relapsed MZL.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Piperidines; Py | 2017 |
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome.
Topics: Adenine; Aged; Cell Transformation, Neoplastic; Disease Progression; Humans; Leukemia, Lymphocytic, | 2017 |
Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.
Topics: Adenine; Animals; Feathers; Humans; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines | 2017 |
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib.
Topics: Adenine; Aged; Biomarkers, Tumor; DNA Methylation; Female; Gene Expression Regulation, Leukemic; Hum | 2018 |
Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report.
Topics: Adenine; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Culture; C | 2018 |
Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Movement; | 2018 |
Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Disease-Free S | 2018 |
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
Topics: Adenine; Aged; Aged, 80 and over; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Elec | 2018 |
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.
Topics: Adenine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Lymphoma, M | 2019 |
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.
Topics: Adenine; Aged; Compassionate Use Trials; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Human | 2019 |
Disseminated mucormycosis due to Lichtheimia corymbifera during ibrutinib treatment for relapsed chronic lymphocytic leukaemia: a case report.
Topics: Abdomen; Adenine; Aged; Fatal Outcome; Humans; Invasive Fungal Infections; Leukemia, Lymphocytic, Ch | 2019 |
Concurrent cerebral aspergillosis and abdominal mucormycosis during ibrutinib therapy for chronic lymphocytic leukaemia.
Topics: Adenine; Adult; Aspergillosis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mucormycosis; Neoplas | 2019 |
The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatitis B e Antigens; He | 2019 |
Ibrutinib-associated Serositis in Mantle Cell Lymphoma.
Topics: Adenine; Aged; Antineoplastic Agents; Humans; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Pip | 2019 |
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Biomarkers, Tumor; CD79 Antigen | 2019 |
Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents, Immunological; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neopl | 2019 |
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acid Substitution; Antineoplastic Agents; Cell C | 2014 |
Ibrutinib: better combined with other drugs?
Topics: Adenine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Fem | 2014 |
Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Bortezomib; Cell Survival; Drug Resistance, Neoplasm; | 2015 |
Understanding cancer cell survival is key to patient survival.
Topics: Adenine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mu | 2015 |
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
Topics: Abnormal Karyotype; Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Delet | 2015 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; | 2016 |
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged, 80 and over; Apoptosis; Cell Transdiffere | 2016 |
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Transformation, Neoplastic | 2016 |
Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.
Topics: Adenine; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Female; Follow-Up Studies; H | 2017 |
Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2017 |
Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hemat | 2017 |
HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Catheter Ablation; Disease-Free S | 2010 |
Interaction between tumour necrosis factor-α gene polymorphisms and substance use on risk of betel quid-related oral and pharyngeal squamous cell carcinoma in Taiwan.
Topics: Adenine; Adult; Aged; Alcohol Drinking; Alleles; Areca; Carcinoma, Squamous Cell; Case-Control Studi | 2011 |
Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load.
Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease-Free Survival; DNA, Viral; Fema | 2013 |
Shorter CAG repeat length in the AR gene is associated with poor outcome in head and neck cancer.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Case-Control Studies; Cytosine; Diseas | 2007 |
Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type.
Topics: Adenine; Adenocarcinoma; Aspartic Acid; Biology; Codon; Colonic Neoplasms; Gene Frequency; Genes, ra | 1993 |